Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/7/2019
SIETES contiene 92793 citas

 
 
 1 a 7 de 7 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H, Martin P, Pol S, Londoño M-C, Hassanein T, Zamor PJ, Zuckerman E, Wan S, Jackson B, Nguyen B-Y, Robertson M, Barr E, Wahl J, Greaves W. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015;386:1537-45. [Ref.ID 99620]
2. Cita con resumen
Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ari ZB, Zhao Y, Brown DD, Wan SH, DiNubile MJ, Nguyen B-Y, Robertson MN, Wahl J, Barr E, Butterton JR. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015;163:40-51. [Ref.ID 99335]
3.
Eron JJ, Young B, Cooper DA, Youle M, DeJesus E, Andrade-Villanueva J, Workman C, Zajdenverg R, Fätkenheuer G, Berger DS, Kumar PN, Rodgers AJ, Shaughnessy MA, Walker ML, Barnard RJO, Miller MD, DiNubile MJ, Nguyen B-Y, Leavitt R, Xu X, Sklar P, for the SWITCHMRK1 and 2 investigators. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010;375:396-407. [Ref.ID 87807]
4.Tiene citas relacionadas Cita con resumen
Lennox JL, DeJesus E, Lazzarín A, Pollard RB, Madruga J, Berger DS, Zhao J, Xu X, Williams-Díaz A, Rodgers AJ, Barnard RJO, Miller MD, DiNubile MJ, Nguyen B-Y, Leavitt R, Sklar P, for the STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374:796-806. [Ref.ID 86738]
5.Tiene citas relacionadas
Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarín A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen B-Y, for the BENCHMRK Study Teams. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008;359:355-65. [Ref.ID 83712]
6.Tiene citas relacionadas
Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarín A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen B-Y, Teppler H, for the BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-54. [Ref.ID 83711]
7.Tiene citas relacionadas Cita con resumen
Grinsztejn B, Nguyen B-Y, Katlama C, Gatell JM, Lazzarín A, Vittecoq D, González CJ, Chen J, Harvey CM, Isaacs RD, for the Protocol 005 Team. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007;369:1261-9. [Ref.ID 79785]
Seleccionar todas
 
 1 a 7 de 7